RA0465

antibody from Oursmab

Targeting: LILRB2 CD85d, ILT4, LIR-2, LIR2, MIR-10, MIR10

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0465

Provider

Oursmab

Product name

Polzastobart (Biosimilar Reference Antibody) (LILRB2)

Antibody type

Monoclonal

Description

Polzastobart is a humanized IgG4 kappa monoclonal antibody developed as an immunomodulatory therapeutic agent. Its primary mechanism of action is the specific and high-affinity binding to the Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2), also known as ILT4 or CD85d. This receptor is predominantly expressed on myeloid cells such as monocytes, macrophages, dendritic cells, and neutrophils. By blocking LILRB2, polzastobart aims to disrupt its interaction with classical and non-classical MHC class I molecules (HLA-G being a high-affinity ligand).

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Polzastobart (Biosimilar Reference Antibody) (LILRB2)-RA0465-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Polzastobart (Biosimilar Reference Antibody) (LILRB2)-RA0465 in a linear range of 15.63¨C125 ng/mL.